BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/6/2016 5:24:00 PM | Browse: 803 | Download: 1227
Publication Name World Journal of Gastroenterology
Manuscript ID 28951
Country/Territory United States
Received
2016-07-22 10:03
Peer-Review Started
2016-07-25 12:11
To Make the First Decision
2016-09-20 10:51
Return for Revision
2016-09-20 13:14
Revised
2016-10-01 00:48
Second Decision
2016-10-21 18:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-10-27 17:22
Articles in Press
2016-10-27 17:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-11-21 16:37
Publish the Manuscript Online
2016-12-06 17:24
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C
Manuscript Source Invited Manuscript
All Author List Esperance AK Schaefer, James Meixiong, Christina Mark, Amy Deik, Daniel L Motola, Dahlene Fusco, Andrew Yang, Cynthia Brisac, Shadi Salloum, Wenyu Lin, Clary B Clish, Lee F Peng and Raymond T Chung
Funding Agency and Grant Number
Funding Agency Grant Number
United States National Institutes of Health DK097855
United States National Institutes of Health DK008191
United States National Institutes of Health DK088951
United States National Institutes of Health DK078772
Corresponding Author Lee F Peng, Associate Medical Director of Liver Transplantation, Associate Professor of Medicine, Temple University Health System, 3509 N. Broad St., 9th Floor, Philadelphia, PA 19140, United States. lee.peng@tuhs.temple.edu
Key Words Apolipoprotein; Lipid; Hepatitis C virus; Gene silencing; Viral replication
Core Tip Hepatitis C virus (HCV) circulates as a very-low-density lipoprotein (VLDL)-like lipoviral particle. Apolipoprotein B100 (apoB100) is the core protein of VLDL, buts its role in HCV has remained incompletely characterized. Use of gene-editing with transcription activator-like effector nucleases permits the characterization of the role of apoB100 in HCV. We demonstrate that apoB100 is required for HCV infection. Loss of apoB100 results in the secretion of HCV virions with an altered lipid composition and limited ability to infect naive cells. Mipomersen, an FDA-approved antisense inhibitor of apoB100, has an anti-HCV effect and limits the viral infectivity.
Publish Date 2016-12-06 17:24
Citation Schaefer EAK, Meixiong J, Mark C, Deik A, Motola DL, Fusco D, Yang A, Brisac C, Salloum S, Lin W, Clish CB, Peng LF, Chung RT. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol 2016; 22(45): 9954-9965
URL http://www.wjgnet.com/1007-9327/full/v22/i45/9954.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i45.9954
Full Article (PDF) WJG-22-9954.pdf
Full Article (Word) WJG-22-9954.doc
Manuscript File 28951-Review.docx
Answering Reviewers 28951-Answering reviewers.pdf
Audio Core Tip 28951-Audio core tip.mp3
Biostatistics Review Certificate 28951-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 28951-Conflict of interest statement.pdf
Copyright License Agreement 28951-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 28951-Grant application form(s).pdf
Institutional Review Board Approval Form or Document 28951-Institutional review board statement.pdf
Peer-review Report 28951-Peer-review(s).pdf
Scientific Misconduct Check 28951-Scientific misconduct check.pdf
Scientific Editor Work List 28951-Scientific editor work list.pdf